Skip to main content
SpringerLink
Log in

Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist’s View

  • Conference paper
  • First Online:
Book cover Alcohol and Cancer

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1032))

Abstract

Chronic alcohol misuse and progressed nonalcoholic fatty liver disease (NAFLD) due to the metabolic syndrome and resulting to nonalcoholic steatohepatitis (NASH) are prime causes of hepatocellular carcinoma (HCC) in Western industrialized countries. The incidence of HCC in NASH-cirrhosis is lower than that of HCC occuring in HCV-related or alcoholic cirrhosis. Up to 20% of cases of alcohol-associated HCC may develop in pre-cirrhotic liver while HCC is also increasingly recognised in pre-cirrhotic NASH raising questions on appropriate surveillance measures for these patient populations. The recently described steatohepatitic subtype of HCC presents with higher frequency in NAFLD compared to alcoholic liver disease (ALD) patients. This review will mainly focus on histopathology and summarize current data on the epidemiology, pathogenesis, diagnosis and management of NAFLD- and ALD-related HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Abou-Alfa G, Sangro B, Morse M, Zhu A, Kim RD, Cheng A-L et al (2016) Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 34(suppl).; abstr TPS3103

    Article  Google Scholar 

  2. Aigelsreiter A, Jens Neumann J, Pichler M, Halasz J, Zatloukal K, Berghold A, et al (2017) Hepatocellular carcinomas with intracellular hyaline bodies have a poor prognosis. Liver Int 37(4):600–610 

    Article  CAS  PubMed  Google Scholar 

  3. Alexander J, Torbenson M, Wu TT, Yeh MM (2013) Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J Gastroenterol Hepatol 28(5):848–854

    Article  PubMed  Google Scholar 

  4. Anstee QM, Seth D, Day CP (2016) Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease. Gastroenterology 150(8):1728–1744

    Article  PubMed  Google Scholar 

  5. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN (2010) The incidence and risk factors of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Hepatology 51:1972–1978

    Article  PubMed  Google Scholar 

  6. Baffy G, Brunt EM, Caldwell SH (2012) Hepatocellular carcinoma in nonalcoholic fatty liver disease: an emerging menace. J Hepatol 56:1384–1391

    Article  PubMed  Google Scholar 

  7. Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C et al (2008) AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 8:200

    Article  PubMed  PubMed Central  Google Scholar 

  8. Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S et al (2016) Role of the galad and balad-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol 14(6):875–886

    Article  CAS  PubMed  Google Scholar 

  9. Bruix J, Merle P, Granito A, Huang Y-H, Bodoky G, Yokosuka O et al (2016) Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial. Ann Oncol 27(suppl 2):ii1–ii3

    Google Scholar 

  10. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P et al (2002) Expanding the natural history of non-alcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134–140

    Article  PubMed  Google Scholar 

  11. Burt AD, Lackner C, Tiniakos D (2015) Diagnosis and assessment of NAFLD: definitions and histopathological classification. Semin Liver Dis 35:207–220

    Article  PubMed  Google Scholar 

  12. Cardinale V, Semeraro R, Torrice A, Gatto M, Napoli C, Bragazzi MC et al (2010) Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. World J Gastrointest Oncol 2:407–416

    Article  PubMed  PubMed Central  Google Scholar 

  13. Charni F, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R et al (2011) Chemokine RANTES promoter dimorphisms and hepatocellular carcinoma occurrence in patients with alcoholic or hepatitis C virus–related cirrhosis. Cancer Epidemiol Biomark Prev 20(7):1439–1446

    Article  CAS  Google Scholar 

  14. Chiang DJ, McCullough AJ (2014) The impact of obesity and metabolic syndrome on alcoholic liver disease. Clin Liver Dis 18(1):157–163

    Article  PubMed  Google Scholar 

  15. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J (2012) Management of HCC. J Hepatol 56:S75–S87

    Article  PubMed  Google Scholar 

  16. Dhanasekaran R, Venkatesh SK, Torbenson MS, Roberts LR (2016) Clinical implications of basic research in hepatocellular carcinoma. J Hepatol 64:736–745

    Article  PubMed  Google Scholar 

  17. Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D et al (2014) Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 60:110–117

    Article  PubMed  Google Scholar 

  18. EASL, EORTC (2012) EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 56(4):908–943

    Article  Google Scholar 

  19. El-Khoueiry AB, Malero I, Crocenzi TS, Welling TH, Yau TC, Yeo W et al (2015) Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): Ca209–040. J Clin Oncol 33(suppl). abstr LBA101

    Article  Google Scholar 

  20. El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134(6):1752–1763

    Article  PubMed  Google Scholar 

  21. Ervik M, Lam F, Ferlay J, Mery L, Soerjomataram I, Bray F (2016) Cancer today. Lyon, France: International Agency for Research on Cancer. Cancer today. Available from: http://gco.iarc.fr/today. Accessed 11 Nov 2016

  22. Faber E (1996) Alcohol and other chemicals in the development of hepatocellular carcinoma. Clin Lab Med 16:377–394

    Article  Google Scholar 

  23. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ (2008) Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 132(11):1761–1766

    PubMed  Google Scholar 

  24. Hall PM (1992) Genetic and acquired factors that influence individual susceptibility to alcohol-associated liver disease. J Gastroenterol Hepatol 7(4):417–426

    Article  CAS  PubMed  Google Scholar 

  25. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL et al (2002) Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36:1206–1213

    Article  CAS  PubMed  Google Scholar 

  26. Hübscher SG (2011) Alcohol-induced liver disease. In: Saxena R (ed) Practical Hepatic Pathology: a diagnostic approach. Elsevier Saunders, Philadelphia, pp 417–433

    Chapter  Google Scholar 

  27. Ikura Y, Tiniakos DG, Tanaka T, Harada K (2017). A case of ruptured HCC in resolving NASH associated with type 2 diabetes: is early detection of diabetes-related HCC feasible? J Diabetes 9(3):311–313

    Google Scholar 

  28. Jain D (2015) Steatohepatitic hepatocellular carcinoma: a metabolic syndrome-associated carcinoma. Histopathology 67(2):267

    Article  PubMed  Google Scholar 

  29. Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D et al (2014) The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomark Prev 1:144–153

    Article  Google Scholar 

  30. Kim H, Oh BK, Roncalli M, Park C, Yoon SM, Yoo JE et al (2009) Large liver cell change in hepatitis B virus-related liver cirrhosis. Hepatology 50:752–762

    Article  CAS  PubMed  Google Scholar 

  31. Knudsen ES, Gopal P, Singal AG (2014) The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol 184(3):574–583

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Kudo M (2004) Hepatocellular carcinoma and NASH. J Gastroenterol 39:409–411

    Article  PubMed  Google Scholar 

  33. Kuper H, Ye W, Broomé U, Romelsjö A, Mucci LA, Ekbom A et al (2001) The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology 34:714–718

    Article  CAS  PubMed  Google Scholar 

  34. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F et al (2001) Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120:1763–7173

    Article  CAS  PubMed  Google Scholar 

  35. Lee FI (1966) Cirrhosis and hepatoma in alcoholics. Gut 7:77–85

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Lee RG, Tsamandas AC, Demetris AJ (1997) Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis. Hepatology 26:1415–1422

    Article  CAS  PubMed  Google Scholar 

  37. Libbrecht LDV, Roskams T (2005) Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 25:16–27

    Article  CAS  PubMed  Google Scholar 

  38. Liu YL, Patman GL, Leathart JB, Piguet AC3, Burt AD1, Dufour JF et al (2014a) Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 61(1):75–81

    Article  CAS  PubMed  Google Scholar 

  39. Liu Y-L, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JBS et al (2014b) TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 5:4309

    Article  CAS  PubMed  Google Scholar 

  40. Makowska Z, Boldanova T, Adametz D, Quagliata L, Vogt JE, Dill MT et al (2016) Gene expression analysis of biopsy samples reveals critical limitations of transcriptome-based molecular classifications of hepatocellular carcinoma. J Pathol 2:80–92

    CAS  Google Scholar 

  41. Manini MA, Sangiovanni A, Fornari F, Piscaglia F, Biolato M, Fanigliulo L (2014) Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. J Hepatol 60(5):995–1001

    Article  PubMed  Google Scholar 

  42. Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski J-P, Ganne N, Hillon P et al (2008) Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 48(2):200–207

    Article  CAS  PubMed  Google Scholar 

  43. Marengo A, Rosso C, Bugianesi E (2016) Liver Cancer: connections with obesity, fatty liver, and Cirrhosis. Annu Rev Med 67:103–117

    Article  CAS  PubMed  Google Scholar 

  44. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS (2002) NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36:1349–1354

    Article  PubMed  Google Scholar 

  45. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS (2005) Alcohol, tobacco and obesity are synergistic factors for hepatocellular carcinoma. J Hepatol 42:218–224

    Article  CAS  PubMed  Google Scholar 

  46. Mittal S, El-Serag HB (2013) Epidemiology of HCC: consider the population. J Clin Gastroenterol 47:S2–S6

    Article  PubMed  PubMed Central  Google Scholar 

  47. Morgan TR, Madayam S, Jamal MM (2004) Alcohol and hepatocellular carcinoma. Gastroenterology 127:587–596

    Article  Google Scholar 

  48. Müllhaupt B, Durand F, Roskams T, Dutkowski P, Heim M (2011) Is tumor biopsy necessary? Liver Transpl 17(Suppl 2):S14–S25

    Article  PubMed  Google Scholar 

  49. Nahon P, Sutton A, Rufat P, Ziol M, Akouche H, Laguillier C et al (2009) Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis. Hepatology 50(5):1484–1493

    Article  CAS  PubMed  Google Scholar 

  50. Oda K, Uto H, Mawatari S, Ido A (2015) Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Clin J Gastroenterol 8:1–9

    Article  PubMed  Google Scholar 

  51. Pahwa A, Beckett K, Channual S, Tan N, Lu DS, Raman SS (2014) Efficacy of the American Association for the Study of Liver Disease and Barcelona criteria for the diagnosis of hepatocellular carcinoma. Abdom Imaging 39:753–760

    Article  PubMed  Google Scholar 

  52. Pais R, Lebray P, Rousseau G, Charlotte F, Esselma G, Savier E et al (2015) Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-related cirrhosis awaiting liver transplants. Clin Gastroenterol Hepatol 13:992–999

    Article  PubMed  Google Scholar 

  53. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V et al (2009) Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 49:851–859

    Article  PubMed  Google Scholar 

  54. Pocha C, Kolly P, Dufour JF (2015) Nonalcoholic fatty liver disease-related hepatocellular carcinoma: a problem of growing magnitude. Semin Liver Dis 35(3):304–317

    Article  PubMed  Google Scholar 

  55. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11:74–80

    Article  PubMed  Google Scholar 

  56. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH et al (2002) Survival, liver failure and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35:1485–1493

    Article  PubMed  Google Scholar 

  57. Reeves HL, Zaki MY, Day CP (2016) Hepatocellular Carcinoma in obesity, type 2 diabetes, and NAFLD. Dig Dis Sci 61:1234–1245

    Article  CAS  PubMed  Google Scholar 

  58. Rinella ME, Sanyal AJ (2015) NAFLD in 2014: genetics, diagnostics and therapeutic advances in NAFLD. Nat Rev Gastroenterol Hepatol 12:65–66

    Article  PubMed  PubMed Central  Google Scholar 

  59. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ (2010) The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52(3):894–903

    Article  CAS  PubMed  Google Scholar 

  60. Salomão M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH (2010) Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 34:1630–1636

    PubMed  Google Scholar 

  61. Salomão M, Remotti H, Vaughan R, Siegel AB, Lefkowitch JH, Moreira RK (2012) The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 43(5):737–746

    Article  PubMed  Google Scholar 

  62. Shibahara J, Ando S, Sakamoto Y, Kokudo N, Fukayama M (2014) Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients. Histopathology 64(7):951–962

    Article  PubMed  Google Scholar 

  63. Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N et al (2002) Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37:154–160

    Article  PubMed  Google Scholar 

  64. Shimizu S, Kiyosawa K, Sodeyama T, Tanaka E, Nakano M (1992) High prevalence of antibody to hepatitis C virus in heavy drinkers with chronic liver diseases in Japan. J Gastroenterol Hepatol 7:30–35

    Article  CAS  PubMed  Google Scholar 

  65. Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P et al (2014) The effect of PNPLA3 on fibrosis progression development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 109:325–334

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Soga M, Kishimoto Y, Kawaguchi J, Nakai Y, Kawamura Y, Inagaki S et al (1999) The FLS mouse: a new inbred strain with spontaneous fatty liver. Lab Animal Sci 49:269–275

    CAS  Google Scholar 

  67. Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ (2009) A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 501:2111–2116

    Article  Google Scholar 

  68. Starley BQ, Calcagno CJ, Harrison SA (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51:1820–1823

    Article  PubMed  Google Scholar 

  69. Stickel F (2015) Alcoholic cirrhosis and hepatocellular carcinoma. Adv Exp Med Biol 815:113–130

    Article  CAS  PubMed  Google Scholar 

  70. Stickel F, Hampe J (2012) Genetic determinants of alcoholic liver disease. Gut 61(1):150–119

    Article  CAS  PubMed  Google Scholar 

  71. Szabo G, Bala S (2013) MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 10(9):542–552

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Tang Y, Banan A, Forsyth CB, Fields JZ, Lau CK, Zhang LJ et al (2008) Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. Alcohol Clin Exp Res 32(2):355–364

    Article  CAS  PubMed  Google Scholar 

  73. Terasaki S, Kaneko S, Kobayashi K, Nonomura A, Nakanuma Y (1998) Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study. Gastroenterology 115:1216–1222

    Article  CAS  PubMed  Google Scholar 

  74. Tiniakos DG, Anstee QM, Burt AD (2017) Fatty liver disease: alcoholic and non-alcoholic. In: Burt AD, Ferrell L, Hübscher S, (eds) MacSween’s pathology of the liver, 7th ed, Edinburgh: Churchill Livingstone 308–371

    Chapter  Google Scholar 

  75. Torbenson M, Schirmacher P (2015) Liver cancer biopsy–back to the future?! Hepatology 61(2):431–433

    Article  PubMed  Google Scholar 

  76. Tsutsumi M, Ishizaki M, Takada A (1996) Relative risk for the development of hepatocellular carcinoma in alcoholic patients with cirrhosis: a multiple logistic-regression coefficient analysis. Alcohol Clin Exp Res 20:758–762

    Article  CAS  PubMed  Google Scholar 

  77. Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB et al (2013) Population-attributable fractions of risk factors for hepatocellular Carcinoma in the United States. Am J Gastroenterol 108(8):1314–1321

    Article  PubMed  PubMed Central  Google Scholar 

  78. Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, Stemmer K et al (2014) Metabolic activation of intrahepatic CD8 + T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 26:549–564

    Article  CAS  PubMed  Google Scholar 

  79. Wong RJ, Cheung R, Ahmed A (2014) Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59:2188–2195

    Article  PubMed  Google Scholar 

  80. Wu TT, Levy M, Correa AM, Rosen CB, Abraham SC (2009) Biliary intraepithelial neoplasia in patients without chronic biliary disease: analysis of liver explants with alcoholic cirrhosis, hepatitis C infection, and noncirrhotic liver diseases. Cancer 115:4564–4575

    Article  PubMed  Google Scholar 

  81. Yamagishi Y, Horie Y, Kajihara M, Konishi M, Ebinuma H, Saito H et al (2004) Hepatocellular carcinoma in heavy drinkers with negative markers for viral hepatitis. Hepatol Res 28:177–183

    Article  CAS  PubMed  Google Scholar 

  82. Yamauchi M, Nakahara M, Maezawa Y, Satoh S, Nishikawa F, Ohata M et al (1993) Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C. Am J Gastroenterol 88:39–43

    CAS  PubMed  Google Scholar 

  83. Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y et al (2011) Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 9:428–433

    Article  PubMed  Google Scholar 

  84. Yasui K, Hashimoto E, Tokushige K, Koike K, Shima T, Kanbara Y et al (2012) Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol Res 42:767–773

    Article  CAS  PubMed  Google Scholar 

  85. Yeligar S, Tsukamoto H, Kalra VK (2009) Ethanol-induced expression of ET-1 and ET-BR in liver sinusoidal endothelial cells and human endothelial cells involves hypoxia-inducible factor-1α and microRNA-199. J Immunol 183(8):5232–5243

    Article  CAS  PubMed  Google Scholar 

  86. Yin H, Hu M, Zhang R, Shen Z, Flatow L, You M (2012) MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1. J Biol Chem 287(13):9817–9826

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M et al (2015) Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62(6):1723–1730

    Article  CAS  PubMed  Google Scholar 

  88. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of non-alcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence and outcomes. Hepatology 64:73–84

    Article  PubMed  Google Scholar 

  89. Zoller H, Tilg H (2016) Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism 65:1151–1160

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

    Dina G. Tiniakos

  2. Department of Pathology, Aretaieion Hospital, Medical School, National & Kapodistrian University of Athens, Athens, Greece

    Dina G. Tiniakos

  3. Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK

    João Maurício & Helen L. Reeves

Authors
  1. Dina G. Tiniakos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. João Maurício
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Helen L. Reeves
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dina G. Tiniakos .

Editor information

Editors and Affiliations

  1. Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, CT, USA

    Vasilis Vasiliou

  2. Distilled Spirits Council of the US, Washington, DC, USA

    Samir Zakhari

  3. Mishra Laboratory, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    Lopa Mishra

  4. Salem Medical Centre, University of Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Helmut K. Seitz

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this paper

Check for updates. Verify currency and authenticity via CrossMark

Cite this paper

Tiniakos, D.G., Maurício, J., Reeves, H.L. (2018). Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist’s View. In: Vasiliou, V., Zakhari, S., Mishra, L., Seitz, H. (eds) Alcohol and Cancer. Advances in Experimental Medicine and Biology, vol 1032. Springer, Cham. https://doi.org/10.1007/978-3-319-98788-0_4

Download citation

Publish with us

Policies and ethics

Search

Navigation